Alpha 2.0
Login Register
» Articles » PMID: 3572470

Intracarotid VP-16 in Malignant Brain Tumors

Overview
Journal J Neurooncol
Publisher Springer
Date 1987 Jan 1
PMID 3572470
Citations 9
Authors
L G Feun
Y Y Lee
W K Yung
N Savaraj
S Wallace
Affiliations
Soon will be listed here.
Abstract

Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

Citing Articles

A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.

Pinkiewicz M, Pinkiewicz M, Walecki J, Zawadzki M Front Oncol. 2022; 12:950167.

PMID: 36212394 PMC: 9539841. DOI: 10.3389/fonc.2022.950167.

The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects.

Philip-Ephraim E, Eyong K, Williams U, Ephraim R ISRN Oncol. 2013; 2012:902178.

PMID: 23304556 PMC: 3529903. DOI: 10.5402/2012/902178.

Intra-arterial chemotherapy of primary brain tumors.

Newton H Curr Treat Options Oncol. 2005; 6(6):519-30.

PMID: 16242056 DOI: 10.1007/s11864-005-0030-1.

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Fulton D, Urtasun R, Forsyth P J Neurooncol. 1996; 27(2):149-55.

PMID: 8699237 DOI: 10.1007/BF00177478.

Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

Paoletti P, Butti G, Knerich R, Gaetani P, Assietti R Acta Neurochir (Wien). 1990; 103(1-2):35-46.

PMID: 2360465 DOI: 10.1007/BF01420190.

References
1.
GREENBERG H, ENSMINGER W, Seeger J, Kindt G, Chandler F, Doan K . Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report. Cancer Treat Rep. 1981; 65(9-10):803-10. View
2.
Tirelli U, DIncalci M, Canetta R, Tumolo S, Franchin G, Veronesi A . Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol. 1984; 2(5):432-7. DOI: 10.1200/JCO.1984.2.5.432. View
3.
Creaven P, Allen L . EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther. 1975; 18(2):221-6. DOI: 10.1002/cpt1975182221. View
4.
STAHELIN H . Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer (1965). 1973; 9(3):215-21. DOI: 10.1016/s0014-2964(73)80021-0. View
5.
Stewart D, Richard M, Hugenholtz H, DENNERY J, Belanger R, Gerin-Lajoie J . Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol. 1984; 2(2):133-9. DOI: 10.1007/BF00177899. View